Lower or heterogeneous expression of target antigens on tumor cells was documented in treatments with anti-EGFRvIII- and IL13Ra2-CAR-T cell therapies and anti-CD19/CD3 BiTE (blinatumomab) [53, 156, 157]. This evidence concerns the gene CD19 and neoplasm.